electroCore (ECOR) 10-Q 13 Aug 20 2020 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 10, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Trading Symbol	ECOR
Entity Registrant Name	electroCore, Inc.
Entity Central Index Key	0001560258
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		44,525,853
Entity File Number	001-38538
Entity Tax Identification Number	20-3454976
Entity Address, Address Line One	150 Allen Road
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Basking Ridge
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07920
City Area Code	973
Local Phone Number	290-0097
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 14,863,128	$ 13,563,791
Marketable securities	3,997,208	10,495,350
Accounts receivable, net	119,486	496,140
Inventories, net	761,301	890,992
Prepaid expenses and other current assets	179,630	1,087,111
Total current assets	19,920,753	26,533,384
Inventories, non-current	6,208,157	6,020,180
Property and equipment, net	290,811	345,236
Operating lease right of use assets	1,245,201	1,430,641
Other assets	993,694	1,132,238
Total assets	28,658,616	35,461,679
Current liabilities:
Accounts payable	1,872,914	5,208,979
Accrued expenses and other current liabilities	2,154,573	3,337,379
Note payable	552,410	111,878
Current portion of operating lease liabilities	495,985	486,445
Total current liabilities	5,075,882	9,144,681
Noncurrent liabilities:
Operating lease liabilities	1,181,768	1,419,880
Note payable, non-current	858,114
Total liabilities	7,115,764	10,564,561
Commitments and contingencies
Stockholders' equity:
Common Stock, par value $0.001 per share; 500,000,000 shares authorized at June 30, 2020 and December 31, 2019; 38,815,145 shares issued and outstanding at June 30, 2020 and 29,835,183 shares issued and outstanding at December 31, 2019	38,815	29,835
Additional paid-in capital	117,154,945	107,752,066
Accumulated deficit	(96,179,975)	(83,479,098)
Accumulated other comprehensive loss	(106,543)	(41,295)
Total electroCore, Inc. stockholders' equity	20,907,242	24,261,508
Noncontrolling interest	635,610	635,610
Total equity	21,542,852	24,897,118
Total liabilities and equity	$ 28,658,616	$ 35,461,679

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	38,815,145	29,835,183
Common stock, shares outstanding	38,815,145	29,835,183

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net sales	$ 752,955	$ 622,743	$ 1,486,726	$ 1,032,344
Cost of goods sold	272,986	254,440	571,101	412,232
Gross profit	479,969	368,303	915,625	620,112
Operating expenses:
Research and development	1,030,530	2,510,429	2,553,644	5,970,252
Selling, general and administrative	5,273,329	9,387,934	11,834,055	20,390,932
Restructuring and other related charges	99,606	849,792	464,606	849,792
Total operating expenses	6,403,465	12,748,155	14,852,305	27,210,976
Loss from operations	(5,923,496)	(12,379,852)	(13,936,680)	(26,590,864)
Other (income)/expense
Interest and other income, net	(11,765)	(279,332)	(74,741)	(645,506)
Other expense	687	0	9,828	16,692
Total other (income)/expense	(11,078)	(279,332)	(64,913)	(628,814)
Loss before income taxes	(5,912,418)	(12,100,520)	(13,871,767)	(25,962,050)
Benefit from income taxes (see Note 15)	1,170,890	0	1,170,890	0
Net loss	$ (4,741,528)	$ (12,100,520)	$ (12,700,877)	$ (25,962,050)
Net loss per share of common stock - Basic and Diluted (see Note 14)	$ (0.13)	$ (0.41)	$ (0.38)	$ (0.89)
Weighted average common shares outstanding - Basic and Diluted (see Note 14)	36,658,797	29,341,574	33,216,512	29,330,442

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (4,741,528)	$ (12,100,520)	$ (12,700,877)	$ (25,962,050)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(109,337)	(55,369)	(64,015)	(11,794)
Unrealized (loss)/gain on securities, net of taxes as applicable	(7,059)	16,271	(1,233)	56,409
Other comprehensive (loss) income	(116,396)	(39,098)	(65,248)	44,615
Comprehensive loss	$ (4,857,924)	$ (12,139,618)	$ (12,766,125)	$ (25,917,435)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)		Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total Electrocore,Inc. Stockholders' Equity	Noncontrolling Interest
Balances, beginning of period at Dec. 31, 2018		$ 66,185,701	$ 29,450	$ 103,791,013	$ (38,331,215)	$ 60,843	$ 65,550,091	$ 635,610
Balances, beginning of period, shares at Dec. 31, 2018			29,450,035
Net loss		(13,861,530)			(13,861,530)		(13,861,530)
Other comprehensive income		83,713				83,713	83,713
Issuance of warrants in settlement of lawsuit		16,692		16,692			16,692
Issuance of stock related to employee compensation plans, net of forfeitures			$ 183	(183)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			183,205
Stock based compensation		744,032		744,032			744,032
Balances, end of period at Mar. 31, 2019		53,168,608	$ 29,633	104,551,554	(52,192,745)	144,556	52,532,998	635,610
Balances, end of period, shares at Mar. 31, 2019			29,633,240
Balances, beginning of period at Dec. 31, 2018		66,185,701	$ 29,450	103,791,013	(38,331,215)	60,843	65,550,091	635,610
Balances, beginning of period, shares at Dec. 31, 2018			29,450,035
Net loss		(25,962,050)
Other comprehensive income		44,615
Balances, end of period at Jun. 30, 2019		41,755,789	$ 29,581	105,278,405	(64,293,265)	105,458	41,120,179	635,610
Balances, end of period, shares at Jun. 30, 2019			29,581,691
Balances, beginning of period at Mar. 31, 2019		53,168,608	$ 29,633	104,551,554	(52,192,745)	144,556	52,532,998	635,610
Balances, beginning of period, shares at Mar. 31, 2019			29,633,240
Net loss		(12,100,520)			(12,100,520)		(12,100,520)
Other comprehensive income		(39,098)				(39,098)	(39,098)
Stock based compensation		726,799	$ (52)	726,851			726,799
Stock based compensation, Shares			(51,549)
Balances, end of period at Jun. 30, 2019		41,755,789	$ 29,581	105,278,405	(64,293,265)	105,458	41,120,179	635,610
Balances, end of period, shares at Jun. 30, 2019			29,581,691
Balances, beginning of period at Dec. 31, 2019		24,897,118	$ 29,835	107,752,066	(83,479,098)	(41,295)	24,261,508	635,610
Balances, beginning of period, shares at Dec. 31, 2019			29,835,183
Net loss		(7,959,349)			(7,959,349)		(7,959,349)
Other comprehensive income		51,148				51,148	51,148
Equity financing commitment fee	[1]		$ 462	(462)
Equity financing commitment fee, shares	[1]		461,676
Issuance of stock related to employee compensation plans, net of forfeitures			$ 125	(125)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			124,568
Stock based compensation		744,865		744,865			744,865
Balances, end of period at Mar. 31, 2020		17,733,782	$ 30,422	108,496,344	(91,438,447)	9,853	17,098,172	635,610
Balances, end of period, shares at Mar. 31, 2020			30,421,427
Balances, beginning of period at Dec. 31, 2019		24,897,118	$ 29,835	107,752,066	(83,479,098)	(41,295)	24,261,508	635,610
Balances, beginning of period, shares at Dec. 31, 2019			29,835,183
Net loss		(12,700,877)
Other comprehensive income		(65,248)
Balances, end of period at Jun. 30, 2020		21,542,852	$ 38,815	117,154,945	(96,179,975)	(106,543)	20,907,242	635,610
Balances, end of period, shares at Jun. 30, 2020			38,815,145
Balances, beginning of period at Mar. 31, 2020		17,733,782	$ 30,422	108,496,344	(91,438,447)	9,853	17,098,172	635,610
Balances, beginning of period, shares at Mar. 31, 2020			30,421,427
Net loss		(4,741,528)			(4,741,528)		(4,741,528)
Other comprehensive income		(116,396)				(116,396)	(116,396)
Issuance of stock		7,831,535	$ 8,028	7,823,507			7,831,535
Issuance of stock, shares			8,028,372
Equity financing commitment fee	[1]		$ 181	(181)
Equity financing commitment fee, shares	[1]		181,273
Financing fees		(167,299)		(167,299)			(167,299)
Issuance of stock related to employee compensation plans, net of forfeitures			$ 184	(184)
Issuance of stock related to employee compensation plans, net of forfeitures, shares			184,073
Stock based compensation		1,002,758		1,002,758			1,002,758
Balances, end of period at Jun. 30, 2020		$ 21,542,852	$ 38,815	$ 117,154,945	$ (96,179,975)	$ (106,543)	$ 20,907,242	$ 635,610
Balances, end of period, shares at Jun. 30, 2020			38,815,145
[1]	Reflects commitment shares issued in accordance with the Company's equity facility purchase agreement with Lincoln Park Capital. For additional information see Note 13. Lincoln Park Stock Purchase Agreement.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (12,700,877)	$ (25,962,050)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,747,623	1,470,831
Depreciation and amortization	193,687	53,632
Amortization of marketable securities discount	(1,396)	(358,640)
Cloud computing arrangement implementation costs		(969,424)
Legal expense settled with stock	156,434
Net noncash lease expense	(50,270)	254,524
Noncash portion of litigation settlement		16,692
Other	10,058	(49,458)
Changes in operating assets and liabilities:
Accounts receivable, net	376,654	(233,370)
Inventories	(58,286)	(3,049,607)
Prepaid expenses and other current assets	897,481	1,310,587
Accounts payable	(1,787,364)	(141,786)
Accrued expenses and other current liabilities	(1,182,806)	(58,340)
Net cash used in operating activities	(12,399,062)	(27,716,409)
Cash flows from investing activities:
Purchase of marketable securities	(3,998,604)	(20,290,317)
Proceeds from maturities of marketable securities	10,500,000	49,266,223
Purchases of property and equipment		(72,825)
Net cash provided by investing activities	6,501,396	28,903,081
Cash flows from financing activities:
Proceeds from shares issued, net of related expenses	5,959,101
Proceeds from note issued	1,410,524
Repayments of note issued	(111,878)
Net cash provided by financing activities	7,257,747
Effect of changes in exchange rates on cash and cash equivalents	(60,744)	(54,972)
Net increase in cash and cash equivalents	1,299,337	1,131,700
Cash and cash equivalents – beginning of period	13,563,791	7,600,284
Cash and cash equivalents – end of period	14,863,128	8,731,984
Supplemental cash flows disclosures:
Proceeds from sale of state net operating losses	1,170,890
Interest paid	5,797
Income taxes paid	4,666	27,795
Supplemental schedule of noncash activity:
Prepaid lease payments included in right of use assets		68,059
Capitalized cloud computing arrangement costs included in accrued expenses and other liabilities		$ 145,144
Accounts payable paid through issuance of common stock	$ 1,548,702

The Company

The Company	6 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company	electroCore, Inc. (“electroCore” or the “Company”) is engaged the commercialization and non-invasive Vagus Stimulation (“ and has primarily focused on (migraine headache). In July 2020, the U.S. Food and Drug Administration (“FDA”) granted the Company an Emergency Use Authorization (EUA) authorizing the use of the Company’s gammaCore Sapphire™ CV nVNS therapy at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated or provide insufficient symptom relief. electroCore, headquartered in New Jersey, has two wholly owned subsidiaries: electroCore Germany GmbH, and electroCore UK Ltd. Effective April 30, 2020, the Company has ceased its operations in Germany, although sales to Germany are still supported by electroCore UK Ltd. In addition, an affiliate, electroCore (Aust) Pty Limited (“electroCore Australia”), is subject to electroCore’s control on a basis other than voting interests and is a variable interest entity (“VIE”), for which electroCore is the primary beneficiary.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(a) Basis of Presentation The accompanying condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2020. The results for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period. (b) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of electroCore and its wholly owned subsidiaries. electroCore Australia, a VIE for which electroCore is the primary beneficiary, is also consolidated with the non-controlled equity presented as non-controlling interest. All intercompany balances and transactions have been eliminated in consolidation. ( c ) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns; valuation of inventory , stock compensation, and contingencies. ( d ) Credit Losses on Financial Instruments In June 2016, the FASB issued guidance on the measurement of credit losses which requires measurement and recognition of expected credit losses for financial assets, including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. The Company adopted this guidance and determined the impact was immaterial on the consolidated to the financial statements. ( e ) Fair Value Measurement In August 2018, the FASB issued guidance which modifies the disclosure requirements for fair value measurements. The guidance is effective for the year ended December 31, 2020. The Company adopted this guidance which was properly reflected in the consolidated financial statements. There were no material changes to the prior disclosure. ( f ) Recent Accounting Standards Not Yet Adopted In December 2019, the FASB issued an update to simplify the accounting for income taxes and improve consistent application by clarifying or amending existing guidance. This guidance is effective for the year ended December 31, 2021. The Company does not expect this guidance to have a material impact on its consolidated financial statements upon adoption.

Risks and Uncertainties

Risks and Uncertainties	6 Months Ended
	Jun. 30, 2020
Risks And Uncertainties [Abstract]
Risks and Uncertainties	Going Concern The Company is subject to risks common to emerging medical device companies, including uncertainties related to commercialization of products and failing to secure additional funding. The Company has experienced significant net losses, and it expects to continue to incur losses for the near future as it operates its sales and marketing infrastructure, and works to increase market acceptance of its gammaCore therapy for the acute treatment of episodic cluster headache (“eCH”), the prevention of cluster headache, and the preventive and acute treatment of migraine. The Company has never been profitable and has incurred net losses in each year since its inception. The Company incurred net losses of $4.7 million and $12.7 million for the three and six months ended June 30, 2020, respectively. On March 27, 2020, the Company and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into an equity facility purchase agreement pursuant to which the Company has the right to sell to Lincoln Park shares of common stock having an aggregate value of up to $25.0 million, subject to certain significant limitations and conditions set forth in the purchase agreement (the “LPC Purchase Agreement”). During the three months ended June 30, 2020, the Company received aggregate proceeds of approximately $6.1 million from sales of common stock to Lincoln Park and private placement transactions. These private placement transactions included sales to certain affiliates and existing shareholders of the Company, including some members of the Company’s board of directors. As of June 30, 2020, the Company had the right to sell under the LPC Purchase Agreement approximately $21.1 million of additional shares of common stock. Subsequent to June 30, 2020, the Company received net aggregate proceeds of approximately $10.3 million from sales of common stock to Lincoln Park transacted under the LPC Purchase Agreement. On May 14, 2020, the Company entered into a Securities Purchase Agreement (Agreement) with its legal counsel pursuant to which it issued 1,564,345, shares of common stock, at a purchase price of $0.99 per share. Upon issuance of the shares, certain of the Company’s outstanding financial obligations to such legal counsel were deemed paid and satisfied in full. In May 2020, the Company received $1.4 million in connection with its Paycheck Protection Program (“PPP”) loan under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). Under the terms of the CARES Act, PPP loan recipients can be granted forgiveness for all or a portion of the loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of certain expenses and loan recipients maintaining their payroll levels over certain required thresholds under the PPP. The terms of any forgiveness also may be subject to further requirements in any regulations and guidelines the Small Business Administration (“SBA”) may adopt. No assurance can be provided that the Company will obtain forgiveness of the PPP Loan in whole or in part. Official guidance and interpretations of the requirements of the program have been limited and have been changing over time. Despite the Company’s good-faith belief that it properly satisfied all eligibility requirements for the PPP loan, there has been increasing scrutiny of public companies that received loans, and there can be no assurance that the Company will not become subject to regulatory or other scrutiny, including a request or requirement for re-payment of some or all of the loan. The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses under the State of New Jersey’s NOL Transfer Program. On May 6, 2020, the Company received a net cash amount of approximately $1.2 million from the sale of its state NOLs and research and development tax credits for the year ended December 31, 2018. The Company’s expected cash requirements for 2020 and beyond are based on the commercial success of its products and its ability to reduce operating expenses. There are significant risks and uncertainties as to its ability to achieve these operating results, including as a result of the adverse impact on its headache business from the COVID-19 pandemic and potential significant investment necessary to generate potential sales of gammaCore Sapphire™ CV. Due to these risks and uncertainties, the There is no assurance that the Company will generate sufficient funding through its operating results or financing activity, raising substantial doubt about the Company’s ability to continue as a going concern within one year of the date these financial statements are issued. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty. Concentration of Revenue Risks The Company earns a significant amount of its revenue (i) in the U.S. from the Department of Veterans Affairs and Department of Defense pursuant to its qualifying contract under the Federal Supply Schedule and open market sales to individual Department of Veterans Affairs facilities and (ii) in the United Kingdom from the National Health Service. Net sales from these two channels represented 83.2% and 87.7% of the Company’s net sales for the three and six months ended June 30, 2020, and 95.3% and 93.0% for the three and six months ended June 30, 2019, respectively. Foreign Currency Exchange Risks The Company has foreign currency exchange risk related to revenue and operating expenses in currencies other than the local currencies in which it operates. The Company is exposed to currency risk from the potential changes in functional currency values of its foreign currency denominated assets, liabilities, and cash flows. COVID-19 Risks and Uncertainties The Company is monitoring the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will impact business partners. While the Company began to experience disruptions during the six months ended June 30, 2020 from the COVID-19 pandemic, it is unable to predict the full impact that the COVID-19 pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets. In addition, because the COVID-19 pandemic affected, among other things, our access to prescribing physicians and their access to headache patients, on March 23, 2020 we suspended our earlier full-year revenue guidance until we could better understand the trajectory of our business, as well as announcing a reduction in our activities, and adjusting our cash runway expectations in response to the potential adverse impact cause by the COVID-19 pandemic. Compared to our earlier expectations, we believe that our results for the six months ended June 30, 2020 reflect a negative impact from, among other things, the global pandemic. Moreover, our expectations for the remainder of 2020 have also been adversely affected by both the uncertainty and potential negative impact of the global pandemic, which we believe may also have had an adverse effect on our access to debt and equity capital markets. Depending upon the duration and severity of the pandemic, the continuing effect on our results and outlook over the long term remains uncertain.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue Recognition	Geographical Net Sales The following table presents net sales disaggregated by geographic area: For the three months ended June 30, For the six months ended June 30, 2020 2019 2020 2019 Geographic Market United States $ 502,801 $ 438,235 $ 958,710 $ 714,700 Europe 246,504 180,706 522,716 307,126 Other 3,650 3,802 5,300 10,518 Total Net Sales $ 752,955 $ 622,743 $ 1,486,726 $ 1,032,344 Performance Obligations Revenue, net of distribution discounts, vouchers, rebates, returns, and co-payment assistance is solely generated from the sales of gammaCore products. Revenue is recognized when delivery of the product is completed. The Company deems control to have transferred upon the completion of delivery because that is the point in which (1) it has a present right to payment for the product, (2) it has transferred the physical possession of the product, (3) the customer has a legal title to the product, (4) the customer has risks and rewards of ownership and (5) the customer has accepted the product. After the products have been delivered and control has transferred, the Company has no remaining unsatisfied performance obligations. Revenue is measured based on the consideration that the Company expects to receive in exchange for gammaCore, which represents the transaction price. The transaction price includes the fixed per-unit price of the product and variable consideration in the form of trade credits, rebates, and co-payment assistance. The per-unit price is based on the Company’s established wholesale acquisition cost less a contractually agreed upon distributor discount with the customer. Trade credits are discounts that are contingent upon a timely remittance of payment and are estimated based on historical experience. Generally, agreed upon payment terms with customers are within 30 days of shipment. Accordingly, contracts with customers do not include a significant financing component. Contract Balances The Company generally invoices the customer and recognizes revenue once its performance obligations are satisfied, at which point payment is unconditional. Accordingly, under ASC 606, the Company’s contracts with customers did not give rise to contract assets or liabilities during the three and six months ended June 30, 2020 and 2019.

Cash, Cash Equivalents and Mark

Cash, Cash Equivalents and Marketable Securities	6 Months Ended
	Jun. 30, 2020
Investments Debt And Equity Securities [Abstract]
Cash, Cash Equivalents and Marketable Securities	The following tables summarize the Company’s cash, cash equivalents and marketable securities as of June 30, 2020 As of June 30, 2020 Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 14,863,315 $ — $ (187 ) $ 14,863,128 U.S. Treasury Bonds $ 3,998,604 $ — $ (1,396 ) $ 3,997,208 Total marketable securities $ 3,998,604 $ — $ (1,396 ) $ 3,997,208 Total cash, cash equivalents, and marketable securities $ 18,861,919 $ — $ (1,583 ) $ 18,860,336 As of December 31, 2019 Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 13,564,252 $ — $ (461 ) $ 13,563,791 U.S. Treasury Bonds $ 10,494,539 $ 811 $ — $ 10,495,350 Total marketable securities $ 10,494,539 $ 811 $ — $ 10,495,350 Total cash, cash equivalents, and marketable securities $ 24,058,791 $ 811 $ (461 ) $ 24,059,141

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Fair Value Hierarchy June 30, 2020 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 14,863,128 $ 14,863,128 $ — $ — Marketable Securities: U.S. treasury bonds 3,997,208 3,997,208 Total $ 18,860,336 $ 18,860,336 $ — $ — Fair Value Hierarchy December 31, 2019 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 13,563,791 $ 13,563,791 $ — $ — Marketable Securities: U.S. treasury bonds 10,495,350 10,495,350 — — Total $ 24,059,141 $ 24,059,141 $ — $ — The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the three and six months ended June 30, 2020 and year ended December 31, 2019. The carrying amount of the Company’s receivables and payables approximate their fair values due to their short maturities.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories	As of June 30, 2020 and December 31, 2019, inventories consisted of the following: June 30, December 31, 2020 2019 Raw materials $ 1,501,680 $ 1,065,345 Work in process 4,757,077 5,314,763 Finished goods 710,701 531,064 Total inventory 6,969,458 6,911,172 Less: noncurrent (6,208,157 ) (6,020,180 ) Total - current $ 761,301 $ 890,992 As of June 30, 2020 and December 31, 2019, the Company’s reserves for obsolete inventory totaled $287,544. The Company records charges for obsolete inventory in cost of goods sold. Noncurrent inventory is comprised of approximately $1.7 million of raw materials and $4.5 million of work in process.

Property and Equipment - Net

Property and Equipment - Net	6 Months Ended
	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Property and Equipment - Net	Property and equipment, net, as of June 30, 2020 June 30, December 31, 2020 2019 Machinery and equipment $ 393,154 $ 393,154 Furniture and fixture 309,045 310,820 Computer equipment 20,783 20,783 Leasehold Improvements 8,880 8,880 Property and equipment - gross 731,862 733,637 Less accumulated depreciation and amortization (441,051 ) (388,401 ) Property and equipment - net $ 290,811 $ 345,236 Property and equipment depreciation and amortization expense for the three and six months ended June 30, 2020 was $25,750 and $52,650, and $25,522 and $53,632 for the three and six months ended June 30, 2019, respectively.

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	Note 9. Leases For the three and six months ended June 30, 2020, the Company recognized lease expense of $119,650 and $273,034, and $213,631 and $413,285 for the three and six months ended June 30, 2019, respectively. This expense does not include non-lease components associated with the lease agreements as the Company elected not to include such charges as part of the lease expense. The tables below provide the details of the right of use assets and lease liabilities: Supplemental Balance Sheet Information for Operating Leases June 30, 2020 December 31, 2019 Operating leases: Operating lease right of use assets $ 1,245,201 $ 1,430,641 Operating lease liabilities: Current portion of operating lease liabilities 495,985 486,445 Noncurrent operating lease liabilities 1,181,768 1,419,880 Total operating lease liabilities $ 1,677,753 $ 1,906,325 Weighted average remaining lease term (in years) 5.7 5.9 Weighted average discount rate 13.75 % 13.75 % Supplemental Statement of Cash Flows Information for Operating Leases Six months ended June 30, 2020 2019 Noncash lease expense $ 178,302 $ 151,771 Change in operating lease liabilities $ (228,572 ) $ 102,753 Future minimum lease payments under non-cancellable operating leases as of June 30, 2020: Remainder of 2020 $ 309,378 2021 743,818 2022 337,254 2023 142,892 2024 146,044 2025 and thereafter 676,260 Total future minimum lease payments 2,355,646 Less: Amounts representing interest (677,893 ) Total $ 1,677,753

Cloud Computing Arrangement

Cloud Computing Arrangement	6 Months Ended
	Jun. 30, 2020
Cloud Computing Arrangement [Abstract]
Cloud Computing Arrangement	Note 10. Cloud Computing Arrangement In 2018, the Company entered into a contract to obtain a cloud computing arrangement (“CCA”). In accordance with ASU 2018-15, the implementation costs incurred in the CCA are deferred and recognized as other assets and are amortized to expense over the noncancelable term of the arrangement. The implementation of this CCA was completed on June 30, 2019.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2020
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses as of June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, 2020 2019 Accrued professional fees 534,618 1,255,494 Accrued bonuses 559,482 804,082 Other 1,060,473 1,277,803 $ 2,154,573 $ 3,337,379

Note Payable

Note Payable	6 Months Ended
	Jun. 30, 2020
Notes Payable [Abstract]
Note Payable	Note 12. Notes Payable Loan Under the PPP On May 4, 2020, the Company received proceeds of $1.4 million in connection with a promissory note (the “Note”) entered into with Citibank, N.A. (the “Lender”) evidencing an unsecured loan (the “Loan”) under the PPP. The PPP is a program of the SBA established under the CARES Act. Under the PPP, the proceeds of the Loan may be used to pay payroll and make certain covered interest payments, lease payments and utility payments (“Qualifying Expenses”). The Company intends to use the entire Loan amount for Qualifying Expenses under the PPP. The interest rate on the Loan is 1.0% per annum. The Note matures on May 2, 2022. On December 2, 2020 (the “First Payment Date”), the Company is required to pay all accrued interest under the Loan that is not forgiven in accordance with the terms of the PPP. Additionally, on the First Payment Date and on the second day of each month thereafter until May 2, 2022, the Company must make equal monthly payments of the amount of principal under the Loan that is not forgiven in accordance with the terms of the PPP and related accrued interest thereon. The Company intends to apply for loan forgiveness under the guidelines of the SBA, which would result in a delay or may eliminate the repayment period, if accepted in whole or in part by the Lender and SBA. The Note contains events of default and other conditions customary for a Note of this type. Under the terms of the CARES Act, PPP loan recipients can be granted forgiveness for all or a portion of the loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of Qualifying Expenses and the Company maintaining its payroll levels over certain required thresholds under the PPP. The terms of any forgiveness also may be subject to further requirements in any regulations and guidelines the SBA may adopt. No assurance can be provided that the Company will obtain forgiveness of the Note in whole or in part. Official guidance and interpretations of the requirements of the program have been limited and have been changing over time. Despite the Company’s good-faith belief that it properly satisfied all eligibility requirements for the PPP loan, there has been increasing scrutiny of public companies that received loans, and there can be no assurance that the Company will not become subject to regulatory or other scrutiny, including a request or requirement for re-payment of some or all of the loan. The Company has accounted for the Loan in accordance with the Financial Accounting Standard Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 470, Debt

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Stockholders Equity Note [Abstract]
Stockholders' Equity	Note 13. Stockholders’ Equity Lincoln Park Purchase Agreement On March 27, 2020, the Company and Lincoln Park entered into an equity facility purchase agreement pursuant to which the Company has the right to sell to Lincoln Park shares of common stock having an aggregate value of up to $25,000,000, subject to certain limitations and conditions set forth in the purchase agreement. Upon entering into the purchase agreement with Lincoln Park, the Company issued an aggregate of 461,676 shares of common stock to Lincoln Park as a commitment fee. The fair value of these shares on the date of issuance was approximately $186,300. In addition, the purchase agreement provides that the Company will issue Lincoln Park an aggregate of 230,838 additional shares of common stock as a further commitment fee based on the first $5,000,000 of shares of common stock issued to Lincoln Park under the Purchase Agreement as Purchase Shares (as such term is defined in the purchase agreement with Lincoln Park). The Company will not receive any cash proceeds from the issuance of any of the foregoing commitment shares. The net proceeds under the purchase agreement to the Company will depend on the frequency and prices at which shares of common stock are sold to Lincoln Park. Actual sales of shares of common stock to Lincoln Park under the purchase agreement and the amount of such net proceeds will depend on a variety of factors, including market conditions, the trading price of the common stock and determinations by the Company as to other available and appropriate sources of funding for the Company. The Company expects to use the proceeds from this agreement for general corporate purposes and working capital. During the three and six months ended June 30, 2020, the Company sold 3,900,000 shares of common stock under the LPC Purchase Agreement, resulting in aggregate proceeds of approximately $3.9 million to the Company. In accordance with the LPC Purchase Agreement, the Company issued an additional 181,273 shares of its common stock to Lincoln Park as a commitment fee. As of June 30, 2020, an additional 49,565 commitment fee shares remain issuable under the LPC Purchase Agreement. See Note 19, Subsequent Events, regarding certain sales to Lincoln Park under the Purchase Agreement subsequent to June 30, 2020. Other Securities Purchase Agreements On April 14, 2020, the Company entered into a Securities Purchase Agreement (“First SPA”) with certain accredited investors pursuant to which the Company agreed to sell an aggregate of 2,058,822 shares of common stock at a purchase price of $0.85 per share for aggregate proceeds to the Company of approximately $1.75 million. Each of the purchasers was an affiliate and/or existing shareholder of the Company, including some members of the Company’s board of directors. In addition, the purchasers were granted customary registration rights as further described in the First SPA. On May 14, 2020, the Company entered into a Securities Purchase Agreement (“Second SPA”) with its legal counsel pursuant to which the Company agreed to issue 1,564,345 shares of common stock, at a purchase price of $0.99 per share. Upon issuance of the shares, certain outstanding financial obligations of the Company owed to its legal counsel were deemed paid and satisfied in full. In addition, the Company’s legal counsel was granted customary registration rights as further described in the Second SPA. During the three and six months ended June 30, 2020, the Company recorded a non-cash charge of $156,434 in connection with this transaction. On May 18, 2020, the Company entered into a third Securities Purchase Agreement (“Third SPA”) with certain accredited investors pursuant to which the Company agreed to sell an aggregate of 505,205 shares of common stock at a purchase price of $0.9178 per share, for aggregate proceeds to the Company of approximately $0.45 million. In addition, the purchasers were granted customary registration rights as further described in the Third SPA.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net Loss Per Share	Note 14. Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding adjusted to give effect to potentially dilutive securities. Restricted stock and unit awards, and stock options have not been included in the diluted loss per share calculation as their inclusion would have had an anti-dilutive effect. The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following: Six months ended June 30, 2020 2019 Outstanding stock options 4,606,407 2,772,209 Nonvested restricted stock and unit awards 1,433,866 2,829,492 Stock purchase warrants 715,199 715,199

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes The Company may be eligible, from time to time, to receive cash from the sale of its Net Operating Losses (“NOLs”) under the State of New Jersey’s NOL Transfer Program. On May 6, 2020, the Company received a net cash amount of approximately $1.2 million from the state NOLs and research and development tax credits for the year ended December 31, 2018. These sale proceeds are included in the Condensed Consolidated Statement of Operations for the three and six months ended June 30, 2020 under the caption Benefit from income taxes. There was no provision for or benefit from income taxes for the three and six months ended June 30, 2019.

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	The following table presents a summary of activity related to stock options during the six months ended June 30, 2020: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, January 1, 2020 3,131,266 $ 8.53 8.9 * Granted 1,844,298 1.28 * Exercised — — Cancelled (369,157 ) 11.00 * Outstanding, June 30, 2020 4,606,407 $ 7.10 8.8 * Exercisable, June 30, 2020 1,892,209 $ 11.66 8.1 * * de minimis The intrinsic value is calculated as the difference between the fair market value at June 30, 2020 and the exercise price per share of the stock options. The options granted to employees generally vest over a four-year period. The following table presents a summary of activity related to restricted stock awards (“RSAs”) granted during the six months ended June 30, 2020: Number of Shares Weighted Average Grant Date Fair Value Nonvested January 1, 2020 127,505 $ 8.09 Granted — — Vested (50,378 ) 9.58 Cancelled (19,806 ) 9.48 Nonvested, June 30, 2020 57,321 $ 6.30 In general, RSAs granted to employees vest over a four-year period. The following table presents a summary of activity related to restricted and deferred stock units (“Stock Units”) granted during the six months ended June 30, 2020: Number of Shares Weighted Average Grant Date Fair Value Nonvested, January 1, 2020 1,241,493 $ 2.86 Granted 732,140 0.91 Vested (328,447 ) 2.85 Cancelled (268,641 ) 4.08 Nonvested, June 30, 2020 1,376,545 $ 1.59 In general, Stock Units granted to employees vest over two to four-year periods. In general, annual share based compensation awards granted to the Company’s non-executive directors vest over one year, and inaugural share based compensation awards vest over three years. The Company recognized stock compensation for its equity awards as follows: Three months ended June 30, Six months ended June 30, 2020 2019 2020 2019 Selling, general and administrative $ 700,275 $ 669,741 $ 1,247,365 $ 1,108,501 Research and development $ 283,222 $ 62,422 $ 469,821 $ 338,978 Cost of goods sold $ 19,261 $ (5,363 ) $ 30,437 $ 23,352 Total unrecognized compensation cost related to unvested awards as of June 30, 2020 was $6.4 million and is expected to be recognized over the next 2.6 years. Valuation Information for Stock-Based Compensation The fair value of each stock option award during the three and six months ended June 30, 2020 and 2019 was estimated on the date of grant using the Black-Scholes model. Expected volatility was based on historical volatility of the Company’s common stock. The risk-free interest rate was based on the average U.S. Treasury rate that most closely resembles the expected life of the related award. The expected term of the award was calculated using the simplified method. No dividend was assumed as the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the current periods presented were: Three months ended June 30, 2020 Six months ended June 30, 2020 Fair value at grant date $ 0.90 $ 0.98 Expected volatility 149.4% 142.1% Risk-free interest rate 0.5% 0.7% Expected holding period, in years 6.1 6.1 Dividend yield — —

Restructuring and Other Related

Restructuring and Other Related Charges	6 Months Ended
	Jun. 30, 2020
Restructuring And Related Activities [Abstract]
Restructuring and Other Related Charges	Note 17. Restructuring and Other Related Charges In January 2020, the Company entered into a separation agreement with a former officer. This agreement required an aggregate severance payment of $190,000 over a six-month period. Also, in January 2020, the Company entered into an agreement with a new employee that requires the unconditional payment of $175,000, in lieu of future severance. Payment is to be made in equal monthly installments over a fourteen-month period. During the three and six months ended June 30, 2020, the Company recorded a charge of $99,606 and $464,606, respectively, in connection with these agreements and other changes that occurred during the three months ended June 30, 2020. This expense is classified as restructuring and other related expense on the Company’s Condensed Consolidated Statements of Operations. The restructuring and other related charges for the three and six months ended June 30, 2019 of $849,792 were related to the Company’s restructuring plan announced on May 29, 2019. The following table provides a summary of the Company’s restructuring and other related charges for the three and six months ended June 30, 2020 and 2019: Three months ended June 30, Six months ended June 30, 2020 2019 2020 2019 Employee separation costs $ 81,164 $ 849,792 $ 271,164 $ 849,792 Payment in lieu of severance — — 175,000 — Other restructuring costs 18,442 — 18,442 — $ 99,606 $ 849,792 $ 464,606 $ 849,792 As of June 30, 2020, $131,667 is payable by the Company in connection with the above described charges. This amount is classified under the caption Accrued expenses and other current liabilities on the Company’s Condensed Consolidated Balance Sheet as of June 30, 2020.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 18. Commitments and Contingencies Stockholders Litigation On July 8, 2019 and August 1, 2019, purported stockholders of the Company served putative class action lawsuits in the Superior Court of New Jersey for Somerset County, captioned Paul Kuehl vs. electroCore, Inc., et al., Docket No. SOM-L 000876-19 and Shirley Stone vs. electroCore, Inc., et al., Docket No. SOM-L 001007-19, respectively. In addition to the Company, the defendants include present and past directors and officers, Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for its IPO; and two of the Company’s stockholders. On August 15, 2019, the Superior Court entered an order consolidating the Kuehl and Stone actions, which are proceeding under Docket No. SOM-L 000876-19. Each plaintiff was appointed a co-lead plaintiff. The plaintiffs filed a consolidated amended complaint, which sought certification of a class of stockholders who purchased common stock in the IPO or whose purchases are traceable to that offering. The consolidated amended complaint alleged that the defendants violated Sections 11, 12(a)(2) and 15 of the Securities Act with respect to the registration statement and related prospectus for the IPO. The complaint sought unspecified compensatory damages, interest, costs and attorneys’ fees. On October 31, 2019, the Company filed a motion to dismiss the complaint or in the alternative to stay the action in favor of the pending federal action (discussed below). On February 21, 2020 the court granted the defendants’ motion to dismiss the consolidated amended complaint with prejudice. On March 2, 2020 the court entered an amended order dismissing the consolidated amended complaint with prejudice. On March 27, 2020, the plaintiffs filed a notice of appeal with the N.J. Superior Court-Appellate Division. The appeal was fully briefed as of July 17, 2020. The date for argument of the appeal has not yet been set. On September 26, 2019 and October 31, 2019, purported stockholders of the Company served putative class action lawsuits in the United States District Court for the District of New Jersey captioned Allyn Turnofsky vs. electroCore, Inc., et al., Case 3:19-cv-18400, and Priewe vs. electroCore, Inc., et al., Case 1:19-cv-19653, respectively. In addition to the Company, the defendants include present and past directors and officers, and Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for the IPO. The plaintiffs each seek to represent a class of stockholders who (i) purchased the Company’s common stock in the IPO or whose purchases are traceable to the IPO, or (ii) who purchased common stock between the IPO and September 25, 2019. The complaints each alleged that the defendants violated Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, with respect to (i) the registration statement and related prospectus for the IPO, and (ii) certain post-IPO disclosures filed with the SEC. The complaints sought unspecified compensatory damages, interest, costs and attorneys’ fees. In the Turnofsky case, on November 25, 2019 several plaintiffs and their counsel moved to be selected as lead plaintiff and lead plaintiff’s counsel. On April 24, 2020, the Court granted the motion of Carole Tibbs and the firm Bragar, Eagel & Squire, P.C. On July 17, 2020 the plaintiffs filed an amended complaint in Turnofsky. In addition to the prior claims, the amended complaint adds an additional director defendant and two investors as defendants, adds a claim against the Company and the underwriters for violating Section 12(a)(2) of the Securities Act. The Priewe case was voluntarily dismissed on February 19, 2020. The Company intends to continue to vigorously defend itself in these matters. However, in light of, among other things, the preliminary stage of these litigation matters, the Company is unable to determine the reasonable probability of loss or a range of potential loss. Accordingly, the Company has not established an accrual for potential losses, if any, that could result from any unfavorable outcome, and there can be no assurance that these litigation matters will not result in substantial defense costs and/or judgements or settlements that could adversely affect the Company’s financial condition. The Company expenses legal fees associated with these stockholder litigations in the period in which they are incurred. Settlement Agreement In January 2019, the Company settled a dispute with one of its former advisors, Madison Global Partners, who had filed a complaint against the Company in the Supreme Court of the State of New York, County of New York (Index No. 652329/2018). As part of that settlement, the Company paid Madison Global $325,000 and issued to Madison Global and its representatives warrants to purchase in the aggregate 62,181 shares of its common stock at prices ranging from $5.68 per share to $12.60 per share. In January 2019, 5,192 warrants with an exercise price of $5.68 were issued and the expense was recognized. All other amounts were accrued in prior accounting periods. The warrants issued are shown in the following table: # Warrants Exercise Price Expiration Dates 8,576 $ 8.86 April 1, 2021 22,253 $ 5.68 March 30, 2022 17,066 $ 12.60 June 30, 2022 14,286 $ 12.60 August 31, 2022

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 19. Subsequent Events Finance and Security Agreement On July 1, 2020, the Company entered into a Commercial Insurance Premium Finance and Security Agreement (the “Agreement”). The Agreement provides for a single loan to the Company of $1.1 million, has a seven-month term, and an annual interest rate of 2.18%. The proceeds from this transaction were used to partially fund the premiums due under some of the Company’s insurance policies. The amounts payable are secured by the Company’s rights under such policies. Sale of Common Stock In July 2020, the Company sold 5,659,676 shares of the Company’s common stock under its purchase agreement with Lincoln Park, resulting in aggregate proceeds of approximately $10.3 million to the Company. In connection with this sale, and pursuant to the provisions of the LPC Purchase Agreement, the Company issued 49,565 shares of its common stock to Lincoln Park relating to the final balance of the commitment fee under the agreement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	(a) Basis of Presentation The accompanying condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2020. The results for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.
Principles of Consolidation	(b) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of electroCore and its wholly owned subsidiaries. electroCore Australia, a VIE for which electroCore is the primary beneficiary, is also consolidated with the non-controlled equity presented as non-controlling interest. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	( c ) Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns; valuation of inventory , stock compensation, and contingencies.
Credit Loss Financial Instrument	( d ) Credit Losses on Financial Instruments In June 2016, the FASB issued guidance on the measurement of credit losses which requires measurement and recognition of expected credit losses for financial assets, including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. The Company adopted this guidance and determined the impact was immaterial on the consolidated to the financial statements.
Fair Value Measurement	( e ) Fair Value Measurement In August 2018, the FASB issued guidance which modifies the disclosure requirements for fair value measurements. The guidance is effective for the year ended December 31, 2020. The Company adopted this guidance which was properly reflected in the consolidated financial statements. There were no material changes to the prior disclosure.
Recent Accounting Standards Not Yet Adopted	( f ) Recent Accounting Standards Not Yet Adopted In December 2019, the FASB issued an update to simplify the accounting for income taxes and improve consistent application by clarifying or amending existing guidance. This guidance is effective for the year ended December 31, 2021. The Company does not expect this guidance to have a material impact on its consolidated financial statements upon adoption.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Summary of Net Sales Disaggregated by Geographic Area	The following table presents net sales disaggregated by geographic area: For the three months ended June 30, For the six months ended June 30, 2020 2019 2020 2019 Geographic Market United States $ 502,801 $ 438,235 $ 958,710 $ 714,700 Europe 246,504 180,706 522,716 307,126 Other 3,650 3,802 5,300 10,518 Total Net Sales $ 752,955 $ 622,743 $ 1,486,726 $ 1,032,344

Cash, Cash Equivalents, and Mar

Cash, Cash Equivalents, and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2020
Investments Debt And Equity Securities [Abstract]
Summary of Cash, Cash Equivalents, and Marketable Securities	The following tables summarize the Company’s cash, cash equivalents and marketable securities as of June 30, 2020 As of June 30, 2020 Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 14,863,315 $ — $ (187 ) $ 14,863,128 U.S. Treasury Bonds $ 3,998,604 $ — $ (1,396 ) $ 3,997,208 Total marketable securities $ 3,998,604 $ — $ (1,396 ) $ 3,997,208 Total cash, cash equivalents, and marketable securities $ 18,861,919 $ — $ (1,583 ) $ 18,860,336 As of December 31, 2019 Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Cash and cash equivalents $ 13,564,252 $ — $ (461 ) $ 13,563,791 U.S. Treasury Bonds $ 10,494,539 $ 811 $ — $ 10,495,350 Total marketable securities $ 10,494,539 $ 811 $ — $ 10,495,350 Total cash, cash equivalents, and marketable securities $ 24,058,791 $ 811 $ (461 ) $ 24,059,141

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Carried at Fair Value	A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Fair Value Hierarchy June 30, 2020 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 14,863,128 $ 14,863,128 $ — $ — Marketable Securities: U.S. treasury bonds 3,997,208 3,997,208 Total $ 18,860,336 $ 18,860,336 $ — $ — Fair Value Hierarchy December 31, 2019 Total Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 13,563,791 $ 13,563,791 $ — $ — Marketable Securities: U.S. treasury bonds 10,495,350 10,495,350 — — Total $ 24,059,141 $ 24,059,141 $ — $ —

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2020
Inventory Disclosure [Abstract]
Inventories Stated at Lower of Cost or Market	As of June 30, 2020 and December 31, 2019, inventories consisted of the following: June 30, December 31, 2020 2019 Raw materials $ 1,501,680 $ 1,065,345 Work in process 4,757,077 5,314,763 Finished goods 710,701 531,064 Total inventory 6,969,458 6,911,172 Less: noncurrent (6,208,157 ) (6,020,180 ) Total - current $ 761,301 $ 890,992

Property and Equipment - Net (T

Property and Equipment - Net (Tables)	6 Months Ended
	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net, as of June 30, 2020 June 30, December 31, 2020 2019 Machinery and equipment $ 393,154 $ 393,154 Furniture and fixture 309,045 310,820 Computer equipment 20,783 20,783 Leasehold Improvements 8,880 8,880 Property and equipment - gross 731,862 733,637 Less accumulated depreciation and amortization (441,051 ) (388,401 ) Property and equipment - net $ 290,811 $ 345,236

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Supplemental Balance Sheet Information for Operating Leases	Supplemental Balance Sheet Information for Operating Leases June 30, 2020 December 31, 2019 Operating leases: Operating lease right of use assets $ 1,245,201 $ 1,430,641 Operating lease liabilities: Current portion of operating lease liabilities 495,985 486,445 Noncurrent operating lease liabilities 1,181,768 1,419,880 Total operating lease liabilities $ 1,677,753 $ 1,906,325 Weighted average remaining lease term (in years) 5.7 5.9 Weighted average discount rate 13.75 % 13.75 %
Supplemental Statement of Cash Flows Information for Operating Leases	Supplemental Statement of Cash Flows Information for Operating Leases Six months ended June 30, 2020 2019 Noncash lease expense $ 178,302 $ 151,771 Change in operating lease liabilities $ (228,572 ) $ 102,753
Future Minimum Lease Payments under Non-Cancellable Operating Leases	Future minimum lease payments under non-cancellable operating leases as of June 30, 2020: Remainder of 2020 $ 309,378 2021 743,818 2022 337,254 2023 142,892 2024 146,044 2025 and thereafter 676,260 Total future minimum lease payments 2,355,646 Less: Amounts representing interest (677,893 ) Total $ 1,677,753

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses as of June 30, 2020 and December 31, 2019 consisted of the following: June 30, December 31, 2020 2019 Accrued professional fees 534,618 1,255,494 Accrued bonuses 559,482 804,082 Other 1,060,473 1,277,803 $ 2,154,573 $ 3,337,379

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share	The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following: Six months ended June 30, 2020 2019 Outstanding stock options 4,606,407 2,772,209 Nonvested restricted stock and unit awards 1,433,866 2,829,492 Stock purchase warrants 715,199 715,199

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Activity Related to Stock Options	The following table presents a summary of activity related to stock options during the six months ended June 30, 2020: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, January 1, 2020 3,131,266 $ 8.53 8.9 * Granted 1,844,298 1.28 * Exercised — — Cancelled (369,157 ) 11.00 * Outstanding, June 30, 2020 4,606,407 $ 7.10 8.8 * Exercisable, June 30, 2020 1,892,209 $ 11.66 8.1 * * de minimis
Summary of Activity Related to Restricted Stock Awards Granted	The following table presents a summary of activity related to restricted stock awards (“RSAs”) granted during the six months ended June 30, 2020: Number of Shares Weighted Average Grant Date Fair Value Nonvested January 1, 2020 127,505 $ 8.09 Granted — — Vested (50,378 ) 9.58 Cancelled (19,806 ) 9.48 Nonvested, June 30, 2020 57,321 $ 6.30
Summary of Activity Related to Restricted Stock and Deferred Stock Units Granted	The following table presents a summary of activity related to restricted and deferred stock units (“Stock Units”) granted during the six months ended June 30, 2020: Number of Shares Weighted Average Grant Date Fair Value Nonvested, January 1, 2020 1,241,493 $ 2.86 Granted 732,140 0.91 Vested (328,447 ) 2.85 Cancelled (268,641 ) 4.08 Nonvested, June 30, 2020 1,376,545 $ 1.59
Schedule of Recognized Stock Compensation for Equity Awards	The Company recognized stock compensation for its equity awards as follows: Three months ended June 30, Six months ended June 30, 2020 2019 2020 2019 Selling, general and administrative $ 700,275 $ 669,741 $ 1,247,365 $ 1,108,501 Research and development $ 283,222 $ 62,422 $ 469,821 $ 338,978 Cost of goods sold $ 19,261 $ (5,363 ) $ 30,437 $ 23,352
Summary of Weighted Average Assumptions Used in Valuing Plans	The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the current periods presented were: Three months ended June 30, 2020 Six months ended June 30, 2020 Fair value at grant date $ 0.90 $ 0.98 Expected volatility 149.4% 142.1% Risk-free interest rate 0.5% 0.7% Expected holding period, in years 6.1 6.1 Dividend yield — —

Restructuring and Other Relat_2

Restructuring and Other Related Charges (Tables)	6 Months Ended
	Jun. 30, 2020
Restructuring And Related Activities [Abstract]
Summary of Restructuring and Other Related Charges	The following table provides a summary of the Company’s restructuring and other related charges for the three and six months ended June 30, 2020 and 2019: Three months ended June 30, Six months ended June 30, 2020 2019 2020 2019 Employee separation costs $ 81,164 $ 849,792 $ 271,164 $ 849,792 Payment in lieu of severance — — 175,000 — Other restructuring costs 18,442 — 18,442 — $ 99,606 $ 849,792 $ 464,606 $ 849,792

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Schedule of Warrants Issued	In January 2019, the Company settled a dispute with one of its former advisors, Madison Global Partners, who had filed a complaint against the Company in the Supreme Court of the State of New York, County of New York (Index No. 652329/2018). As part of that settlement, the Company paid Madison Global $325,000 and issued to Madison Global and its representatives warrants to purchase in the aggregate 62,181 shares of its common stock at prices ranging from $5.68 per share to $12.60 per share. In January 2019, 5,192 warrants with an exercise price of $5.68 were issued and the expense was recognized. All other amounts were accrued in prior accounting periods. The warrants issued are shown in the following table: # Warrants Exercise Price Expiration Dates 8,576 $ 8.86 April 1, 2021 22,253 $ 5.68 March 30, 2022 17,066 $ 12.60 June 30, 2022 14,286 $ 12.60 August 31, 2022

Risks and Uncertainties - Addit

Risks and Uncertainties - Additional Information (Details) - USD ($)

Jul. 01, 2020

May 14, 2020

May 06, 2020

May 04, 2020

Jul. 31, 2020

May 31, 2020

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2019

Mar. 31, 2019

Jun. 30, 2020

Jun. 30, 2019

Mar. 27, 2020

Risks And Uncertainties [Line Items]

Net losses

$ 4,741,528

$ 7,959,349

$ 12,100,520

$ 13,861,530

$ 12,700,877

$ 25,962,050

Proceeds from note issued

$ 1,410,524

Net Sales | Government Contracts Concentration Risk

Risks And Uncertainties [Line Items]

Percentage of net sales

83.20%

95.30%

87.70%

93.00%

Promissory Note | Citibank, N.A. | Paycheck Protection Program

Risks And Uncertainties [Line Items]

Proceeds from note issued

$ 1,400,000

$ 1,400,000

Stock Purchase Agreement | Lincoln Park

Risks And Uncertainties [Line Items]

Value of shares issued

$ 5,000,000

Aggregate proceeds from sale of common stock

$ 3,900,000

Additional shares of common stock

21,100,000

Stock Purchase Agreement | Lincoln Park | Subsequent Event

Risks And Uncertainties [Line Items]

Aggregate proceeds from sale of common stock

$ 10,300,000

$ 10,300,000

Stock Purchase Agreement | Lincoln Park | Private Placement Transaction

Risks And Uncertainties [Line Items]

Aggregate proceeds from sale of common stock

$ 6,100,000

Stock Purchase Agreement | Lincoln Park | Maximum

Risks And Uncertainties [Line Items]

Value of shares issued

$ 25,000,000

Securities Purchase Agreement

Risks And Uncertainties [Line Items]

Issuance of stock, shares

1,564,345

Shares issued price per share

$ 0.99

New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Risks And Uncertainties [Line Items]

Sale of net operating losses

$ 1,200,000

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Sales Disaggregated by Geographic Area (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 752,955	$ 622,743	$ 1,486,726	$ 1,032,344
United States
Disaggregation Of Revenue [Line Items]
Total Net Sales	502,801	438,235	958,710	714,700
Europe
Disaggregation Of Revenue [Line Items]
Total Net Sales	246,504	180,706	522,716	307,126
Other
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 3,650	$ 3,802	$ 5,300	$ 10,518

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details)	6 Months Ended
	Jun. 30, 2020USD ($)
Revenue From Contract With Customer [Abstract]
Revenue remaining unsatisfied performance obligation	$ 0
Payment term for customers	30 days

Cash, Cash Equivalents, and M_2

Cash, Cash Equivalents, and Marketable Securities - Summary of Cash, Cash Equivalents, and Marketable Securities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Cash and Cash Equivalents, Amortized Cost	$ 14,863,315	$ 13,564,252
Cash and Cash Equivalents, Unrealized (Loss)	(187)	(461)
Cash and cash equivalents	14,863,128	13,563,791
Marketable securities, Amortized Cost	3,998,604	10,494,539
Marketable securities, Unrealised Gain		811
Marketable securities, Unrealized (Loss)	(1,396)
Marketable securities, Fair Value	3,997,208	10,495,350
Cash, cash equivalents and marketable securities, Amortized Cost	18,861,919	24,058,791
Cash, cash equivalents and marketable securities, Unrealized Gain		811
Cash, cash equivalents, and marketable securities, Unrealized (Loss)	(1,583)	(461)
Cash, cash equivalents, and marketable securities, Fair Value	18,860,336	24,059,141
U.S. Treasury Bonds
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost	3,998,604	10,494,539
Marketable securities, Unrealised Gain		811
Marketable securities, Unrealized (Loss)	(1,396)
Marketable securities, Fair Value	3,997,208	10,495,350
Cash, cash equivalents, and marketable securities, Fair Value	$ 3,997,208	$ 10,495,350

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Assets and Liabilities Carried at Fair Value (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 14,863,128	$ 13,563,791
Marketable Securities	18,860,336	24,059,141
U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	3,997,208	10,495,350
(Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	14,863,128	13,563,791
Marketable Securities	18,860,336	24,059,141
(Level 1) | U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities	$ 3,997,208	$ 10,495,350

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value of assets, transfer from level 1 to level 2	$ 0	$ 0	$ 0
Fair value of assets transfer from level 2 to level 1	0	0	0
Fair value of liabilities, transfer from level 1 to level 2	0	0	0
Fair value of liabilities, transfer from level 2 to level 1	0	0	0
Fair value of assets, transfers into level 3	0	0	0
Fair value of assets, transfers out of level 3	0	0	0
Fair value of liabilities, transfers Into level 3	0	0	0
Fair value of liabilities, transfers out of level 3	$ 0	$ 0	$ 0

Inventory - Inventories Stated

Inventory - Inventories Stated at Lower of Cost or Market (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,501,680	$ 1,065,345
Work in process	4,757,077	5,314,763
Finished goods	710,701	531,064
Total inventory	6,969,458	6,911,172
Less: noncurrent	(6,208,157)	(6,020,180)
Total - current	$ 761,301	$ 890,992

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory [Line Items]
Noncurrent inventory raw materials	$ 1,700,000	$ 1,700,000
Noncurrent inventory work in process	4,500,000	4,500,000
Inventory Valuation and Obsolescence [Member]
Inventory [Line Items]
Inventory raw materials	$ 287,544	$ 287,544

Property and Equipment - Net -

Property and Equipment - Net - Schedule of Property and Equipment, Net (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 731,862	$ 733,637
Less accumulated depreciation and amortization	(441,051)	(388,401)
Property and equipment - net	290,811	345,236
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	393,154	393,154
Furniture and Fixture
Property Plant And Equipment [Line Items]
Property and equipment - gross	309,045	310,820
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	20,783	20,783
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 8,880	$ 8,880

Property and Equipment - Net _2

Property and Equipment - Net - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 25,750	$ 25,522	$ 52,650	$ 53,632

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Recognized lease expenses	$ 119,650	$ 213,631	$ 273,034	$ 413,285

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information for Operating Leases (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Operating leases:
Operating lease right of use assets	$ 1,245,201	$ 1,430,641
Current portion of operating lease liabilities	495,985	486,445
Noncurrent operating lease liabilities	1,181,768	1,419,880
Total operating lease liabilities	$ 1,677,753	$ 1,906,325
Weighted average remaining lease term (in years)	5 years 8 months 12 days	5 years 10 months 24 days
Weighted average discount rate	13.75%	13.75%

Leases - Supplemental Statement

Leases - Supplemental Statement of Cash Flows Information for Operating Leases (Details) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Noncash lease expense	$ 178,302	$ 151,771
Change in operating lease liabilities	$ (228,572)	$ 102,753

Leases - Future Minimum Lease P

Leases - Future Minimum Lease Payments under Non-Cancellable Operating Leases (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Remainder of 2020	$ 309,378
2021	743,818
2022	337,254
2023	142,892
2024	146,044
2025 and thereafter	676,260
Total future minimum lease payments	2,355,646
Less: Amounts representing interest	(677,893)
Total	$ 1,677,753	$ 1,906,325

Cloud Computing Arrangement - A

Cloud Computing Arrangement - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Cloud Computing Arrangement [Line Items]
Amortization of cloud computing arrangement	$ 70,518	$ 141,037
Remaining lease term	3 years	3 years
Other Assets
Cloud Computing Arrangement [Line Items]
Net book value of cloud computing arrangement	$ 940,248	$ 940,248	$ 1,081,284

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 534,618	$ 1,255,494
Accrued bonuses	559,482	804,082
Other	1,060,473	1,277,803
Accrued expenses	$ 2,154,573	$ 3,337,379

Note Payable - Additional Infor

Note Payable - Additional Information (Details) - USD ($)	May 04, 2020	May 31, 2020	Jun. 30, 2020
Notes Payable [Line Items]
Proceeds from borrowings			$ 1,410,524
Promissory Note | Citibank, N.A. | Paycheck Protection Program
Notes Payable [Line Items]
Proceeds from borrowings	$ 1,400,000	$ 1,400,000
Interest rate on the Loan	1.00%
Note, maturity date	May 2, 2022

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	May 18, 2020	May 14, 2020	Apr. 14, 2020	Jun. 30, 2020	Jun. 30, 2020	Mar. 27, 2020	Dec. 31, 2019
Stock Purchase Agreement [Line Items]
Common stock, shares issued				38,815,145	38,815,145		29,835,183
Stock Purchase Agreement | Lincoln Park
Stock Purchase Agreement [Line Items]
Value of shares issued						$ 5,000,000
Common stock, shares issued				3,900,000	3,900,000	461,676
Fair value of common stock shares issued						$ 186,300
Additional commitment shares issued				181,273	181,273
Aggregate proceeds from sale of common stock					$ 3,900,000
Additional commitment shares Issuable				49,565	49,565
Stock Purchase Agreement | Lincoln Park | Maximum
Stock Purchase Agreement [Line Items]
Value of shares issued						$ 25,000,000
Additional commitment shares issued						230,838
First SPA
Stock Purchase Agreement [Line Items]
Aggregate proceeds from sale of common stock			$ 1,750,000
Aggregate number of shares issued			2,058,822
Shares issued. price per share			$ 0.85
Second SPA
Stock Purchase Agreement [Line Items]
Shares issued. price per share		$ 0.99
Issuance of stock, shares		1,564,345
Non-cash charge				$ 156,434	$ 156,434
Third SPA
Stock Purchase Agreement [Line Items]
Aggregate proceeds from sale of common stock	$ 450,000
Aggregate number of shares issued	505,205
Shares issued. price per share	$ 0.9178

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Outstanding stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,606,407	2,772,209
Nonvested restricted stock and unit awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,433,866	2,829,492
Stock purchase warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	715,199	715,199

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	May 06, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating Loss Carryforwards [Line Items]
Provision for income taxes		$ (1,170,890)	$ 0	$ (1,170,890)	$ 0
New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Operating Loss Carryforwards [Line Items]
Sale of net operating losses	$ 1,200,000

Stock Based Compensation - Summ

Stock Based Compensation - Summary of Activity Related to Stock Options (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Outstanding, January 1, 2020	3,131,266
Number of Options, Granted	1,844,298
Number of Options, Cancelled	(369,157)
Number of Options, Outstanding, June 30, 2020	4,606,407	3,131,266
Number of Options, Exercisable, June 30, 2020	1,892,209
Weighted Average Exercise Price, Outstanding, January 1, 2020	$ 8.53
Weighted Average Exercise Price, Granted	1.28
Weighted Average Exercise Price, Cancelled	11
Weighted Average Exercise Price, Outstanding, June 30, 2020	7.10	$ 8.53
Weighted Average Exercise Price, Exercisable, June 30, 2020	$ 11.66
Weighted Average Remaining Contractual Term (Years), Outstanding, January 1, 2020	8 years 9 months 18 days	8 years 10 months 24 days
Weighted Average Remaining Contractual Term (Years), Exercisable, June 30, 2020	8 years 1 month 6 days

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2020USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation cost related to unvested awards	$ 6.4
Unrecognized compensation expected to be recognized	2 years 7 months 6 days
RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
Stock Units | Non-Executive Director
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	1 year
Stock Units | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	2 years
Stock Units | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years

Stock Based Compensation - Su_2

Stock Based Compensation - Summary of Activity Related to Restricted Stock Awards Granted (Details) - RSAs	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Nonvested, January 1,2020 | shares	127,505
Number of Shares, Vested | shares	(50,378)
Number of Shares, Cancelled | shares	(19,806)
Number of Shares, Nonvested, June 30, 2020 | shares	57,321
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2020 | $ / shares	$ 8.09
Weighted Average Grand Date Fair Value, Vested | $ / shares	9.58
Weighted Average Grand Date Fair Value, Cancelled | $ / shares	9.48
Weighted Average Grand Date Fair Value, Nonvested, June 30, 2020 | $ / shares	$ 6.30

Stock Based Compensation - Su_3

Stock Based Compensation - Summary of Activity Related to Restricted Stock and Deferred Stock Units Granted (Details) - Stock Units	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Nonvested, January 1,2020 | shares	1,241,493
Number of Shares, Granted | shares	732,140
Number of Shares, Vested | shares	(328,447)
Number of Shares, Cancelled | shares	(268,641)
Number of Shares, Nonvested, June 30, 2020 | shares	1,376,545
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2020 | $ / shares	$ 2.86
Weighted Average Grand Date Fair Value, Granted | $ / shares	0.91
Weighted Average Grand Date Fair Value, Vested | $ / shares	2.85
Weighted Average Grand Date Fair Value, Cancelled | $ / shares	4.08
Weighted Average Grand Date Fair Value, Nonvested, June 30, 2020 | $ / shares	$ 1.59

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Recognized Stock Compensation for Equity Awards (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 700,275	$ 669,741	$ 1,247,365	$ 1,108,501
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	283,222	62,422	469,821	338,978
Cost of Goods Sold
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 19,261	$ (5,363)	$ 30,437	$ 23,352

Stock Based Compensation - Su_4

Stock Based Compensation - Summary of Weighted Average Assumptions Used in Valuing Plans (Details) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair value at grant date	$ 0.90	$ 0.98
Expected volatility	149.40%	142.10%
Risk-free interest rate	0.50%	0.70%
Expected holding period, in years	6 years 1 month 6 days	6 years 1 month 6 days

Restructuring and Other Relat_3

Restructuring and Other Related Charges - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Restructuring Cost And Reserve [Line Items]
Restructuring and other related expense		$ 99,606	$ 849,792	$ 464,606	$ 849,792
Accrued Expense and Other Current Liabilities
Restructuring Cost And Reserve [Line Items]
Amount payable in connection with restructuring charges		131,667		131,667
Employee Severance | Former Officer
Restructuring Cost And Reserve [Line Items]
Aggregate severance payment	$ 190,000	$ 81,164	$ 849,792	271,164	$ 849,792
Employee Severance | New Employee
Restructuring Cost And Reserve [Line Items]
Aggregate severance payment	$ 175,000			$ 175,000

Restructuring and Other Relat_4

Restructuring and Other Related Charges - Summary of Restructuring and Other Related Charges (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Restructuring Cost And Reserve [Line Items]
Other restructuring costs		$ 18,442		$ 18,442
Restructuring and other related charges		99,606	$ 849,792	464,606	$ 849,792
Employee Severance | Former Officer
Restructuring Cost And Reserve [Line Items]
Severance costs	$ 190,000	$ 81,164	$ 849,792	271,164	$ 849,792
Employee Severance | New Employee
Restructuring Cost And Reserve [Line Items]
Severance costs	$ 175,000			$ 175,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Jul. 17, 2020Defendant	Jan. 31, 2019USD ($)Dispute$ / sharesshares
Former Financial Advisor
Class Of Warrant Or Right [Line Items]
Number of dispute settled | Dispute		1
Cash paid in settlement agreement | $		$ 325,000
Former Financial Advisor | Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase common stock | shares		62,181
Exercise price of warrants		$ 5.68
Former Financial Advisor | Common Stock | Minimum
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		5.68
Former Financial Advisor | Common Stock | Maximum
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 12.60
Former Financial Advisor | Common Stock | Warrants with Exercise Price of $5.68
Class Of Warrant Or Right [Line Items]
Warrants to purchase common stock | shares		5,192
Subsequent Event
Class Of Warrant Or Right [Line Items]
Number of investors as defendants | Defendant	2

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Warrants Issued (Details) - Former Financial Advisor	Jan. 31, 2019$ / sharesshares
Warrant One
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	8,576
Exercise Price | $ / shares	$ 8.86
Expiration Dates	Apr. 1, 2021
Warrant Two
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	22,253
Exercise Price | $ / shares	$ 5.68
Expiration Dates	Mar. 30, 2022
Warrant Three
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	17,066
Exercise Price | $ / shares	$ 12.60
Expiration Dates	Jun. 30, 2022
Warrant Four
Class Of Warrant Or Right [Line Items]
Number of Warrants | shares	14,286
Exercise Price | $ / shares	$ 12.60
Expiration Dates	Aug. 31, 2022

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ in Millions	Jul. 01, 2020	Jul. 31, 2020	Jun. 30, 2020	Mar. 27, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Common stock, shares issued			38,815,145		29,835,183
Stock Purchase Agreement | Lincoln Park
Subsequent Event [Line Items]
Common stock, shares issued			3,900,000	461,676
Aggregate proceeds from issuance of common stock			$ 3.9
Subsequent Event | Stock Purchase Agreement | Lincoln Park
Subsequent Event [Line Items]
Common stock, shares issued		5,659,676
Aggregate proceeds from issuance of common stock	$ 10.3	$ 10.3
Commitment shares issued		49,565
Subsequent Event | Commercial Insurance Premium Finance and Security Agreement
Subsequent Event [Line Items]
Loan	$ 1.1
Debt instrument, term	7 months
Interest rate on the Loan	2.18%